# Congenica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/congenica

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.congenica.com
- Total disclosed funding: $88M
- Latest round: Series C (Mar 3, 2021)
- Investors on record: 14

## About

Based in Cambridge, the UK, founded in 2014, Congenica Ltd., is a digital health company enabling genomic medicine for the research used for analysis and interpretation of genomic data. In September 2025, SeqOne SAS, a portfolio company of Elaia Partners, Omnes Capital, Merieux Equity Partners, Supernova Invest, and Irdi Capital Investissement, agreed to acquire Congenica Ltd. from Cambridge Innovation Capital, UK Department of Health and Genomics England, Amadeus Capital Partners, Parkwalk Advisors, Future Planet Capital, Healthlink Capital, Shenzhen Huada Gene Technology Co., Ltd., Digital China Health Technologies Co., Ltd., Downing, IDO Investments, Legal and General Group, Puhua Capital, Tencent Investment, Xeraya Capital, and and QVentures.

The company's clinical decision support and analysis platform, Sapientia, offers analysis, interpretation, and analysis of the entire human genome data. Congenica's platform provides researchers with genome analysis, enabling them to interpret next-generation sequencing data, maximize cash throughput, and improve health outcomes. The company provides analysis using automation and AI technology, without the requirement of manual intervention. Additionally, the company provides Congenica Express Database and the variant prioritization tool, Exomiser, which allows variant prioritization in the Congenica NGS analysis platform to improve diagnostic yields by an average of 30%, as well as Congenica Neuro and Congenica Prenatal specialist modules. The company also offers congenica 3.1 to reduce time spent on genetic analysis as well as interpretational and reporting services.

## Funding rounds

- Series C, Mar 3, 2021, $2.6M — QVentures
- Series C, Nov 9, 2020, $51M — Legal and General Group, Tencent Investment, Parkwalk Advisors, Xeraya Capital, Cambridge Innovation Capital, Puhua Capital, IDO Investments, Downing
- Series B, Apr 30, 2019, $17M — Parkwalk Advisors, Digital China Health Technologies Co., Ltd.
- Series B, Apr 24, 2017, $2.6M — Shenzhen Huada Gene Technology Co., Ltd., Healthlink Capital, Future Planet Capital
- Series B, Feb 13, 2017, $10M — Amadeus Capital Partners, Parkwalk Advisors, Cambridge Innovation Capital
- Series A, Apr 1, 2015, $3.3M — Amadeus Capital Partners, Cambridge Innovation Capital
- Seed, Nov 26, 2014, $0.8M — Cambridge Innovation Capital

## Investors

- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Seed, Series A, Series B, Series C
- Amadeus Capital Partners (https://capitalatlas.ai/funds/amadeus-capital-partners) — Series A, Series B
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series B, Series C
- Shenzhen Huada Gene Technology Co., Ltd. — Series B
- Healthlink Capital — Series B
- Future Planet Capital (https://capitalatlas.ai/funds/future-planet-capital) — Series B
- Digital China Health Technologies Co., Ltd. — Series B
- Legal and General Group — Series C
- Tencent Investment — Series C
- Xeraya Capital (https://capitalatlas.ai/funds/xeraya-capital) — Series C
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series C
- IDO Investments (https://capitalatlas.ai/funds/ido-investments) — Series C
- Downing (https://capitalatlas.ai/funds/downing) — Series C
- QVentures (https://capitalatlas.ai/funds/qventures) — Series C